Overview

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Status:
Not yet recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Conjupro Biotherapeutics, Inc.
Collaborator:
CSPC-NBP Pharmaceutical Co., Ltd.